Inka Health to Lead AI-Driven Oncology Project with OneMedNet

Onco-Innovations Limited has announced that its subsidiary, Inka Health Corp., has been selected by OneMedNet Corporation to lead a significant data analytics initiative in oncology. The project aims to enhance the development of cancer therapies through the creation of external control arms (ECAs) using OneMedNet's regulatory-grade patient data. This approach is seen as a potentially faster and more cost-effective alternative to traditional clinical trials.

The collaboration focuses on leveraging real-world data to replicate trial results without the typical time and cost constraints. Inka Health will use its SynoGraph platform, which integrates machine learning, to validate an ECA for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer.

This project aligns with the growing use of real-world evidence (RWE) in drug development and aims to accelerate market entry for new cancer therapies. The collaboration with OneMedNet is expected to yield a scientific abstract for submission to ISPOR Europe 2025.